Opinion

Video

Key Takeaways on the Evolving NMIBC Treatment Landscape

Author(s):

Gordon A. Brown, DO,Siamak Daneshmand, MD

The panel concludes by offering key takeaways on the evolving treatment landscape for BCG-unresponsive non–muscle invasive bladder cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Videos
      Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
      Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
      Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
      Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
      Study data point to gender disparities in oncology research citations
      Study data point to gender disparities in oncology research citations
      Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
      Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
      Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
      Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
      Urinary bladder | Image Credit: © magicmine - stock.adobe.com
      Expert describes implications of neoadjuvant durvalumab approval in MIBC
      Sima Porten, MD, on gene-environment interactions in bladder cancer development
      Sima Porten, MD, on gene-environment interactions in bladder cancer development
      3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
      How rBCG EAP could open up access for Anktiva in bladder cancer
      Betty Wang, MD, discusses studies from the 2025 EAU meeting
      Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
      Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
      Joshua J. Meeks, MD, PhD, discusses the impact of neoadjuvant durvalumab approval in MIBC
      Related Content
      FDA updates in urology: April 2025
      May 1st 2025

      FDA updates in urology: April 2025

      Hannah Clarke
      A recap of the FDA submissions and regulatory decisions in urology from April 2025.
      medical depiction of bladder cancer
      May 31st 2023

      Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

      Urology Times staff
      In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
      Sam S. Chang, MD, MBA
      April 28th 2025

      Nogapendekin alfa inbakicept shows high CR, avoidance of cystectomy in NMIBC

      Benjamin P. Saylor
      In cohort A, the cystectomy-free rate at 36 months was 84%.
      Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease
      May 26th 2022

      Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

      Urology Times staff
      “We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.
      Blur image of hospital corridor | Image Credit: © jakkapan - stock.adobe.com
      April 27th 2025

      Estimated DOR of 2 years is seen with UGN-102 in LG-IR-NMIBC

      Benjamin P. Saylor
      The investigators reported that the median Kaplan-Meier estimate of DOR was 24.2 months.
      Mark D. Tyson II, MD, MPH
      April 27th 2025

      Cretostimogene yields high CR rate in BCG-unresponsive NMIBC

      Benjamin P. Saylor
      "97% [of patients] remain progression free, and 84.5% avoided cystectomy, highlighting cretostimogene’s bladder-sparing potential,” said Mark D. Tyson II, MD, MPH.
      © 2025 MJH Life Sciences

      All rights reserved.